Tim A. Smith
Research Subjects
Research Interests
Tim A. Smith has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Amit Gaggar
University of Alabama at Birmingham
1 shared publication - Bryan Garcia
Gregory Fleming James Cystic Fibrosis Research Center, The University of Alabama at Birmingham, Birmingham, AL 35294, USA
1 shared publication - Dana L. Goodwin
Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, 1900 University Blvd, Birmingham, USA
1 shared publication - George M. Solomon
University of Alabama, Birmingham, Alabama, USA
1 shared publication - Jacque L. Carden
Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, 1900 University Blvd, Birmingham, USA
1 shared publication - Kevin Leon
Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, 1900 University Blvd, Birmingham, USA
1 shared publication
Latest Publications
- Open Access
- 14 February 2018
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 18 (1) , 1-5
Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients
Infection with Burkholderia cepacia complex (Bcc) results in a heterogeneous clinical course ranging from asymptomatic colonization of the airways to fulminant respiratory failure in patients with cystic fibrosis (CF). Early eradication of Pseudomonas aeruginosa improves clinical outcomes. The efficacy and clinical outcomes following implementation of an eradication protocol for Bcc are less well understood. We developed and implemented a single center Bcc eradication protocol that included an intensive combination of intravenous, inhaled, and oral antibiotic therapies based on in vitro sensitivities. We conducted a retrospective cohort analysis of clinical outcomes compared to patients with chronic Bcc infection. Six patients were identified as having a newly acquired Bcc colonization and were placed on the eradication protocol. Sequential sputum samples after completion of the protocol demonstrated sustained clearance of Bcc in all patients. Lung function and nutritional status remained stable in the year following eradication. Clearance of Bcc from sputum cultures using a standardized protocol was successful at one year and was associated with clinical stability.
- 14 February 2018
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 18 (1) , 1-5
Open AccessImplementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients
Infection with Burkholderia cepacia complex (Bcc) results in a heterogeneous clinical course ranging from asymptomatic colonization of the airways to fulminant respiratory failure in patients with cystic fibrosis (CF). Early eradication of Pseudomonas aeruginosa improves clinical outcomes. The efficacy and clinical outcomes following implementation of an eradication protocol for Bcc are less well understood. We developed and implemented a single center Bcc eradication protocol that included an intensive combination of intravenous, inhaled, and oral antibiotic therapies based on in vitro sensitivities. We conducted a retrospective cohort analysis of clinical outcomes compared to patients with chronic Bcc infection. Six patients were identified as having a newly acquired Bcc colonization and were placed on the eradication protocol. Sequential sputum samples after completion of the protocol demonstrated sustained clearance of Bcc in all patients. Lung function and nutritional status remained stable in the year following eradication. Clearance of Bcc from sputum cultures using a standardized protocol was successful at one year and was associated with clinical stability.